Back to Rankings

MIRM

MirumA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The checked evidence supports a constructive post-print read: strong Q1 product sales, a 2026 guide raise, positive recent VISTAS and AZURE-1 milestone language in the earnings update, and a cash position that management says supports operations for at least 12 months [#8-K-2026-05-06] [#10-Q-2026-05-06].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.8.
What can break
Late-2026 pipeline value remains highly dependent on successful AZURE and EXPAND readouts, with normal biotech binary-risk around efficacy, safety, and regulatory interpretation.
Momentum
72
Value
49
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $118.00 · Bull $135.00 · Bear $82.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $124.64
Why
Momentum72 · Δ7d -4.8
Value49 · Δ7d +0.1
Sentiment73 · Δ7d +6.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
72
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.8
Δ21d
-1.3
Value
49
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
73
33% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
+19.6
Why this grade

Composite grade A. Momentum 71.5 / Value 48.7 / Sentiment 73.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$5.87B
Beta
0.49
Shares Out
51.68M
P/E (TTM) · Derived
-244.2
P/S (TTM)
8.28
P/FCF (TTM)
88.12
Rev YoY
+47.2%
EPS YoY
+117.1%
Gross Margin
+79.9%
Op Margin
-8.9%
Net Debt
$27.77M
Current Ratio
3.31
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology